The Supreme Court is expected to rule by late June on whether FIFRA preempts Roundup failure-to-warn claims, with 61,000 suits and a $7.25B settlement in the balance.
The Supreme Court heard oral argument in *Monsanto v. Durnell* and is expected to issue a decision by late June 2026 on whether the Federal Insecticide, Fungicide, and Rodenticide Act preempts state-law failure-to-warn claims tied to Roundup, Bayer's glyphosate-based herbicide [1]. The central question is whether EPA's approval of a pesticide label, which carried no cancer warning, forecloses plaintiffs from arguing under state tort law that the label was inadequate [1]. Observers following argument described the court as closely divided, with no clear majority signal emerging from the bench [1].
The case reaches the court as the final major legal bottleneck in years of Roundup mass-tort litigation. Bayer, the German pharmaceutical and agrochemical company that acquired Monsanto in 2018, faces approximately 61,000 pending claims alleging that glyphosate causes non-Hodgkin's lymphoma [2]. The justices took up the FIFRA preemption question after lower courts produced conflicting results, and the case now sits at the intersection of federal regulatory authority and state products-liability law [1]. Argument occurred before the full court in Washington, D.C., with a ruling expected before the term closes [1].
The preemption question carries stakes well beyond *Durnell* itself. If the court holds that FIFRA preempts state failure-to-warn claims whenever EPA has approved the label in question, the decision would effectively extinguish most of the remaining 61,000 suits and establish a broad liability shield for pesticide manufacturers operating under EPA-approved labeling regimes [2]. A ruling for plaintiffs, by contrast, would leave Bayer exposed to continued litigation and potentially billions in additional judgments, replicating the outcomes that produced earlier multi-hundred-million-dollar jury verdicts [1].
Bayer is simultaneously pursuing a parallel settlement track. A Missouri Circuit Court granted preliminary approval to a $7.25 billion class settlement intended to resolve the bulk of remaining claimants [1]. A final approval hearing is scheduled for July 2026, and the opt-out deadline for class members fell on June 4, 2026 [1]. The dual-track posture, Supreme Court decision combined with an accelerated settlement, reflects Bayer's effort to cap exposure regardless of how the justices rule [2]. If the court rules in Bayer's favor on preemption, the settlement's value to plaintiffs diminishes sharply; a plaintiff-side ruling could spur additional opt-outs and renewed litigation pressure before final approval is entered [1].